The 21 most recent market catalysts affecting $JAGX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 25, 2026
Corporate Catalyst
Bearish
Impact 65
Jaguar Health Announces Issuance Of 182,091 Shares To Streeterville Capital For $1.67832M Reduction In 2021 Note Balance; 2025 Streeterville Note Fully Paid And Cancelled Following Exchange For 547,898 Shares
Jaguar Health (JAGX) announced the issuance of shares to Streeterville Capital in exchange for a reduction in its 2021 note balance and the full cancellation of its 2025 note. This…
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 85
Jaguar Health Stock Slides Thursday: What's Happening?
Jaguar Health (JAGX) converted a portion of its debt with Streeterville Capital into equity, issuing 547,898 new shares. This move, while reducing the company's debt burden by over…
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 75
Jaguar Health shares are trading lower after the company converted about $5.05 million of debt into common stock, resulting in shareholder dilution.
The conversion of debt into common stock, while a common strategy to improve a company's balance sheet by reducing liabilities, inherently leads to an increase in the number of out…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Reported Earlier: Jaguar Health Issues 547,898 Common Shares To Streeterville Capital To Retire ~$5.05M Of Outstanding Promissory Note
Jaguar Health (JAGX) engaged in a debt-for-equity swap, issuing shares to Streeterville Capital to reduce a significant portion of a promissory note. This transaction is positive f…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 60
Jaguar Health Files Supplement To Offer Up To ~$9.82M Of Common Stock Under At-The-Market Offering Program
Jaguar Health is utilizing an ATM offering program to raise capital by selling up to $9.82 million worth of common stock. This is a continuation of their existing ATM program, whic…
Sep 23, 2026
Market Technicals
Bearish
Impact 85
Jaguar Health Stock Plunges Wednesday: What's Happening?
Jaguar Health (JAGX) experienced extreme volatility, with shares surging over 1,100% on Tuesday due to an FDA fee waiver for its Mytesi drug, a move significantly amplified by a lo…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
Jaguar Health Stock Surged 1200% on Tuesday: Here's Why JAGX Stock Is Trending After Hours
Jaguar Health (JAGX) experienced an extraordinary 1200% surge in its stock price after the FDA granted waivers for Prescription Drug User Fee Act (PDUFA) fees for two of its therap…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 92
Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars Today
Jaguar Health's stock experienced an unprecedented surge of 1190.64% after announcing FDA fee waivers for Mytesi and Canalevia-CA1. This is a major positive catalyst as it signific…
Sep 22, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's After-Market Session
This filing, generated by an automated content engine, highlights the volatility in the healthcare sector during Tuesday's after-market session. Several small-cap healthcare compan…
Sep 22, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Tuesday's Intraday Session
This filing, generated by Benzinga's automated content engine, reports on the intraday performance of 12 healthcare stocks, categorizing them into 'gainers' and 'losers.' It matter…
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 75
Jaguar Health shares are trading higher after the company announced that the FDA granted the Napo Pharmaceutical's request for a fee waiver associated with the Prescription Drug User Fee Act for Mytesi.
This headline is a significant positive catalyst for Jaguar Health (JAGX). The FDA's fee waiver for Mytesi under PDUFA directly reduces the company's operational costs and regulato…
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 55
FDA Grants Jaguar Health Family Company Napo Pharma's Request For Waiver Of Fee Associated With PDUFA For Mytesi For 2027 Fiscal Year
Jaguar Health announced that its family company, Napo Pharmaceuticals, received a waiver from the FDA for the Prescription Drug User Fee Act (PDUFA) fee for Mytesi for the 2027 fis…
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 85
Jaguar Health shares are trading lower after the company announced it will effect 1-for-15 reverse stock split on September 17.
A reverse stock split, especially one as aggressive as 1-for-15, is almost universally perceived as a negative signal by the market. Companies typically resort to this measure to a…
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 65
Jaguar Health To Effect 1-For-15 Reverse Stock Split Of Common Stock On September 17
Jaguar Health is implementing a 1-for-15 reverse stock split, effective September 17, 2026. This action is primarily driven by the need to comply with Nasdaq's minimum bid price re…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 75
Jaguar Health shares are trading lower after the company announced all pediatric MVID patients in pivotal crossover clinical trial have entered the extension phase to receive blinded doses of crofelemer.
This headline directly impacts Jaguar Health (JAGX) as it concerns a key clinical trial for their drug, crofelemer, targeting pediatric MVID. The market's negative reaction, despit…
Aug 19, 2026
Corporate Catalyst
Bearish
Impact 92
Jaguar Health Q2 EPS $(15.70) Up From $(358.94) YoY, Sales $1.225M Down From $2.979M YoY
Jaguar Health's Q2 earnings report reveals a mixed bag for investors. While the company dramatically reduced its per-share losses from $(358.94) to $(15.70), indicating some operat…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Jaguar Health’s Napo Pharma Satisfies Conditions Required To Receive Payment Of Non-Dilutive $2M Holdback Amount From Future Pak Related To US Commercial Licensing Agreement
Jaguar Health announced that its subsidiary, Napo Pharma, has satisfied the conditions to receive a $2 million holdback payment from Future Pak, related to a U.S. commercial licens…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 55
Jaguar Health Says Findings Of Exploratory Surveys Of Dog Owners And Veterinary Oncologists Support Commercial Opportunity For Neonorm Dog, New Extension Of Jaguar's Neonorm Franchise
Jaguar Health (JAGX) announced that exploratory surveys of dog owners and veterinary oncologists support the commercial opportunity for its new product, Neonorm Dog. This is signif…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
Jaguar Health Registered Resale Of Up To 40.8M Shares Of Common Stock By Selling Stockholder
The registration of a significant number of shares for resale by a selling stockholder, especially 40.8 million shares for a company like Jaguar Health, creates an overhang on the …
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
Jaguar Health Registered Resale Of Up To 40.8M Shares Of Common Stock By Selling Stockholde
This headline indicates a significant potential increase in the float of Jaguar Health (JAGX) shares, as existing stockholders are registering to sell up to 40.8 million shares. Th…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.